Abstract：An 8-year-old girl who had experienced intermittent cough and fever over a 3 year period, was admitted after experiencing a recurrence for one month. One year ago the patient experienced a recurrent oral mucosal ulcer. Physical examination showed vitiligo in the skin of the upper right back. Routine blood tests and immune function tests performed in other hospitals had shown normal results. Multiple lung CT scans showed pulmonary infection. The patient had recurrent fever and cough and persistent presence of some lesions after anti-infective therapy. The antitubercular therapy was ineffective. Routine blood tests after admission showed agranulocytosis. Gene detection was performed and she was diagnosed with dyskeratosis congenita caused by homozygous mutation in RTEL1. Patients with dyskeratosis congenita with RTEL1 gene mutation tend to develop pulmonary complications. Since RTEL1 gene sequence is highly variable with many mutation sites and patterns and can be inherited via autosomal dominant or recessive inheritance, this disease often has various clinical manifestations, which may lead to missed diagnosis or misdiagnosis. For children with unexplained recurrent pulmonary infection, examinations of the oral cavity, skin, and nails and toes should be taken and routine blood tests should be performed to exclude dyskeratosis congenita. There are no specific therapies for dyskeratosis congenita at present, and when bone marrow failure and pulmonary failure occur, hematopoietic stem cell transplantation and lung transplantation are the only therapies. Androgen and its derivatives are effective in some patients. Drugs targeting the telomere may be promising for patients with dyskeratosis congenita.
Imai H, Sunaga N, Kaira K, et al. Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma[J]. Intern Med, 2009, 48(5):301-306.
[5]
Savage SA. Dyskeratosis congenita[M]//Pagon RA, Adam MP, Ardinger HH, et al. Gene reviews®.[Internet]. Seattle (WA):University of Washington, Seattle; 1993-2017.
Verra F, Kouzan S, Saiag P, et al. Bronchoalveolar disease in dyskeratosis congenita[J]. Eur Respir J, 1992, 5(4):497-499.
[8]
Samuel BP, Duffner UA, Abdel-Mageed AS, et al. Pulmonary arteriovenous malformations in dyskeratosis congenita[J]. Pediatr Dermatol, 2015, 32(4):e165-166.
[9]
Goldfarb S, Sullivan KE, Jyonouchi S. A patient with X-linked dyskeratosis congenita presenting with bronchiolitis obliterans requiring lung transplantation and immunodeficiency[J]. Pediatr Pulmonol, 2013, 48(1):91-93.
[10]
Reimann C, Kloeckener-Gruissem B, Niemeyer CM, et al. Late manifestation of dyskeratosis congenita presenting as chronic dermal ulcer in a 37-year-old man[J]. J Eur Acad Dermatol Venereol, 2008, 22(7):897-898.
[11]
Iraji F, Jamshidi K, Pourazizi M, et al. Dyskeratosis congenita without oral involvement:A rare hereditary disease[J]. Oman Med J, 2015, 30(3):212-215.
[12]
Fernández García MS, Teruya-Feldstein J.The diagnosis and treatment of dyskeratosis congenita:a review[J]. J Blood Med, 2014, 5:157-167.
[13]
Vannie JB, Sarek G, Boulton SJ. RTEL1:functions of a diseaseassociated helicase[J]. Trends Cell Biol, 2014, 24(7):416-425.
Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive[J]. Eur Respir J, 2016, 48(6):1710-1720.
[16]
Stanley SE, Noth I, Armanios M. What the genetics "RTEL" ing us about telomeres and pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2015, 191(6):608-610.
[17]
Islam A, Rafiq S, Kirwan M, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol[J]. Br J Haematol, 2013, 162(6):854-856.
[18]
Barbaro P, Vedi A. Survival after hematopoietic stem cell transplant in patients with dyskeratosis congenita:Systematic review of the literature[J]. Biol Blood Marrow Transplant, 2016, 22(7):1152-1158.
[19]
Giri N, Lee R, Faro A, et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita:Case report and systematic literature review[J]. BMC Blood Disord., 2011, 11:3.
